Highlights

  • US Congress extended the Rare Pediatric Disease Priority Review Voucher program until September 2029.
  • Neuren holds multiple rare pediatric disease designations linked to its NNZ-2591 development programs.
  • FDA approval under the program may allow eligibility for a transferable priority review voucher.

Neuren Pharmaceuticals Ltd (ASX:NEU) has noted that the United States Congress has reauthorized the Rare Pediatric Disease Priority Review Voucher (PRV) program through 30 September 2029, with the decision confirmed on 3 February 2026 EST. The extension maintains an existing regulatory incentive framework that applies to drug developers pursuing therapies for designated rare pediatric diseases and continues to support FDA review pathways for qualifying treatments.

Under the PRV framework, drug developers that secure US Food and Drug Administration (FDA) approval for therapies targeting designated rare pediatric diseases may receive a priority review voucher. This voucher can be used to accelerate the FDA review of another drug application or transferred to another developer through a sale.

How the PRV Program Works
The PRV program allows eligible companies to reduce FDA review timelines for a separate product by several months. Alternatively, vouchers can be sold in the secondary market, where transaction values have varied over time. In January 2026, a disclosed transaction valued a voucher at approximately USD 200 million, reflecting continued market interest in the program.

Reauthorization of the program ensures continuity for companies already holding rare pediatric disease designations and for those advancing clinical development in qualifying indications.

Neuren’s Designations and Development Pipeline
Neuren Pharmaceuticals currently holds Rare Pediatric Disease designations for its second drug candidate, NNZ-2591, across three indications: Phelan-McDermid syndrome, Pitt Hopkins syndrome, and Angelman syndrome. FDA approval of NNZ-2591 in any one of these designated conditions would meet the eligibility criteria for a priority review voucher, with Neuren retaining full ownership rights.

NNZ-2591 is being developed for multiple neurodevelopmental disorders, with Phase 2 clinical trials completed in the three syndromes. Each program has also received orphan drug designation in both the United States and the European Union, a status that provides regulatory incentives intended to support development for rare and serious diseases.

Commercial Context and Existing Approved Therapy
Neuren’s marketed therapy, trofinetide, is approved in the United States for the treatment of Rett syndrome under the brand names DAYBUE and DAYBUE STIX. The company has granted Acadia Pharmaceuticals Inc. an exclusive worldwide licence for the development and commercialisation of trofinetide.

The reauthorization of the PRV program preserves an established regulatory pathway relevant to Neuren’s ongoing clinical and regulatory activities in pediatric neurological disorders.

Share Performance
Neuren Pharmaceuticals traded at AUD 13.24, down by 9.50% on 5 February 2026.

With the US Congress extending the Rare Pediatric Disease Priority Review Voucher program to September 2029, Neuren Pharmaceuticals continues to operate within a regulatory framework that supports rare pediatric drug development. Market participants are monitoring progress across NNZ-2591 clinical programs and regulatory milestones, while the PRV program remains a recognized component of the broader US drug approval landscape.

FAQs

Q1. What is the Rare Pediatric Disease Priority Review Voucher program?
It is a US FDA program that awards vouchers for priority review to developers of approved rare pediatric disease therapies.

Q2. Which Neuren drug is linked to PRV eligibility?
NNZ-2591, designated for Phelan-McDermid, Pitt Hopkins, and Angelman syndromes.

Q3. Can PRVs be sold to other companies?
Yes, PRVs may be transferred or sold, depending on the holder’s decision.